| 98.02 Real-Time Quote |  +0.10 / +0.10%Today’s Change | 80.09 Today|||52-Week Range 102.04 | +6.34% Year-to-Date |
| Don't Get Too Worked Up Over Shire's Latest Numbers 1:06am / MotleyFool.com | Shire Settles Lawsuit with Teva - Analyst Blog Jun 03 / Zacks.com |
| Previous close | 97.92 |
| Today’s open | 97.82 |
| Day’s range | 97.55 - 98.79 |
| Volume | 150,153 |
| Average volume (3 months) | 636,143 |
| Market cap | $18.1B |
| Dividend yield | 0.53% |
| Earnings growth (last year) | -14.55% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +10.00% |
| Revenue growth (last year) | +9.69% |
| P/E ratio | NM |
| Price/Sales | 3.64 |
| Price/Book | 4.82 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALXNAlexion Pharmaceutic... | +1.59 | +1.71% |
| VRTXVertex Pharmaceutica... | +2.48 | +3.18% |
| ACTActavis Inc | +1.51 | +1.24% |
| ZTSZoetis Inc | -0.77 | -2.40% |
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | $1.64 |
| Annual revenue (last year) | $4.7B |
| Annual profit (last year) | $746.8M |
| Net profit margin | 15.92% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chief Executive Officer & Director Flemming Ørnskov, MD, MBA |
CFO, Director, CAO & Investor Relations Contact Graham C. Hetherington |
Corporate headquarters Dublin, -- |
.
